Evidence map›Paper›PMID 27425378›Full record

ArticleThe Journal of pathology2016

Collaboration of cancer-associated fibroblasts and tumour-associated macrophages for neuroblastoma development.

Okito Hashimoto, Makiko Yoshida, Yu-Ichiro Koma, Tomoko Yanai, Daiichiro Hasegawa, Yoshiyuki Kosaka, Noriyuki Nishimura, Hiroshi Yokozaki

Open access · hybridAbstract read
In one paragraph

Article in The Journal of pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed
9.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 184 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Myeloid cell-derived apCAFs promote HNSCC progression by regulating proportion of CD4Journal of experimental & clinical cancer research : CR · 2025
    Article
  20. Review

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Okito HashimotoDivision of Pathology, Department of Pathology, Kobe University Graduate School of Medicine, Kobe, Japan.
Makiko YoshidaDepartment of Pathology, Kobe Children's Hospital, Kobe, Japan.
Yu-Ichiro KomaDivision of Pathology, Department of Pathology, Kobe University Graduate School of Medicine, Kobe, Japan.
Tomoko YanaiDepartment of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Daiichiro HasegawaDepartment of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Yoshiyuki KosakaDepartment of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.
Noriyuki NishimuraDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Hiroshi YokozakiDivision of Pathology, Department of Pathology, Kobe University Graduate School of Medicine, Kobe, Japan. hyoko@med.kobe-u.ac.jp.
Kobe Children's Hospital · JPKobe University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroblastoma is the most common extracranial solid tumour in children and is histologically classified by its Schwannian stromal cells. Although having fewer Schwannian stromal cells is generally associated with more aggressive phenotypes, the exact roles of other stromal cells (mainly macrophages and fibroblasts) are unclear. Here, we examined 41 cases of neuroblastoma using immunohistochemistry for the tumour-associated macrophage (TAM) markers CD68, CD163, and CD204, and a cancer-associated fibroblast (CAF) marker, alpha smooth muscle actin (αSMA). Each case was assigned to low/high groups on the basis of the number of TAMs or three groups on the basis of the αSMA-staining area for CAFs. Both the number of TAMs and the area of CAFs were significantly correlated with clinical stage, MYCN amplification, bone marrow metastasis, histological classification, histological type, and risk classification. Furthermore, TAM settled in the vicinity of the CAF area, suggesting their close interaction within the tumour microenvironment. We next determined the effects of conditioned medium of a neuroblastoma cell line (NBCM) on bone marrow-derived mesenchymal stem cells (BM-MSCs) and peripheral blood mononuclear cell (PBMC)-derived macrophages in vitro. The TAM markers CD163 and CD204 were significantly up-regulated in PBMC-derived macrophages treated with NBCM. The expression of αSMA by BM-MSCs was increased in NBCM-treated cells. Co-culturing with CAF-like BM-MSCs did not enhance the invasive ability but supported the proliferation of tumour cells, whereas tumour cells co-cultured with TAM-like macrophages had the opposite effect. Intriguingly, TAM-like macrophages enhanced not only the invasive abilities of tumour cells and BM-MSCs but also the proliferation of BM-MSCs. CXCL2 secreted from TAM-like macrophages plays an important role in tumour invasiveness. Taken together, these results indicate that PBMC-derived macrophages and BM-MSCs are recruited to a tumour site and activated into TAMs and CAFs, respectively, followed by the formation of favourable environments for neuroblastoma progression. © 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Indexed as

Antigens, CDCancer-Associated FibroblastsCarcinogenesisCell Line, TumorCell ProliferationCoculture TechniquesGanglioneuroblastomaHumansLeukocytes, MononuclearMacrophagesMesenchymal Stem CellsNeuroblastomaN-Myc Proto-Oncogene ProteinAntigens, CDN-Myc Proto-Oncogene Proteincancer-associated fibroblastMSR1, macrophage scavenger receptor 1neuroblastomatumour-associated macrophagetumour microenvironment

Identifiers

PMID27425378
PMCPMC5095779
OpenAlexW2487956862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.